Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Infracyanine is a specific iodine-free formulation of indocyanine green (ICG), a water-soluble tricarbocyanine dye used as a diagnostic fluorescent imaging agent. Developed for clinical use in procedures such as sentinel lymph node (SLN) mapping, it is being evaluated by the Association Pour La Recherche des Thérapeutiques Innovantes en Cancérologie (ARTC) specifically for women with early-stage breast cancer. In the FLUO-BREAST clinical trial, Infracyanine is administered via periareolar injection, where it binds to endogenous albumin and migrates through the lymphatic system. This allows for the real-time visualization of lymphatic drainage and the identification of sentinel nodes using near-infrared (NIR) fluorescence imaging, providing a non-radioactive alternative to traditional technetium-99m isotope lymphoscintigraphy.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Infracyanine.